Antiestrogenic therapies in solid cancers and multiple myeloma

Area of Science:

• Endocrinology and oncology, focusing on hormone-driven cancers.
• Molecular biology of estrogen receptors (ER alpha and ER beta) and their role in gene transcription.

Background:

• Estrogens are crucial for human health but also implicated in breast cancer development and progression.
• Endocrine therapy combats estrogen-dependent cancers by reducing hormone availability or blocking its action.
• Antiestrogens (AEs) include selective estrogen receptor modulators (SERMs) with mixed profiles and selective estrogen receptor downregulators (SERDs) that degrade ERs.

Purpose of the Study:

• To review antiestrogenic therapies for solid cancers, including estrogen-dependent and independent types.
• To present recent findings on the application of AEs in treating multiple myeloma.
• To highlight limitations of current antiestrogen therapies, such as tamoxifen, in breast cancer treatment.

Main Methods:

• Review of existing literature on antiestrogenic therapies for various cancers.
• Presentation of novel research data on the use of AEs against multiple myeloma.
• Analysis of tamoxifen's limitations, including side effects and resistance mechanisms.

Main Results:

• Tamoxifen, a widely used antiestrogen, exhibits limitations like side effects and resistance in breast cancer treatment.
• AEs show potential in treating both estrogen-dependent and independent solid tumors.
• Emerging research explores AE efficacy in multiple myeloma.

Conclusions:

• Novel antiestrogen drug delivery systems hold promise for enhancing therapeutic effects by targeting tumor cells.
• Improved drug delivery can potentially overcome limitations associated with current antiestrogen therapies.
• Targeted delivery of AEs may improve treatment outcomes and reduce adverse effects in cancer patients.